EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel

Sandra M Rocha iD, Daniel Nascimento, Rafaella S Coelho, Ana Margarida Cardoso, Luís A Passarinha iD, Sílvia Socorro iD, Cláudio J Maia iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sandra M Rocha und 6 weiteren Autor:innen. Beteiligte Einrichtung: CICS-UBI-Health Sciences Research Center, Universidade da Beira Interior, 6201-506 Covilhã, Portugal. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, CICS-UBI projects, National funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Six Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1) protein has been indicated as an overexpressed oncoprotein in prostate cancer (PCa), associated with tumor progression and aggressiveness. Taxane-based antineoplastic drugs such as paclitaxel, docetaxel, or cabazitaxel, have been investigated in PCa treatment, namely for the development of combined therapies with the improvement of therapeutic effectiveness. This study aimed to evaluate the expression of STEAP1 in response to taxane-based drugs and assess whether the sensitivity of PCa cells to treatment with paclitaxel, docetaxel, or cabazitaxel may change when the STEAP1 gene is silenced. Thus, wild-type and STEAP1 knockdown LNCaP and C4-2B cells were exposed to paclitaxel, docetaxel or cabazitaxel, and STEAP1 expression, cell viability, and survival pathways were evaluated. The results obtained showed that STEAP1 knockdown or taxane-based drugs treatment significantly reduced the viability and survival of PCa cells. Relatively to the expression of proliferation markers and apoptosis regulators, LNCaP cells showed a reduced proliferation, whereas apoptosis was increased. However, the effect of paclitaxel, docetaxel, or cabazitaxel treatment was reversed when combined with STEAP1 knockdown. Besides, these chemotherapeutic drugs may stimulate the cell growth of PCa cells knocked down for STEAP1. In conclusion, this study demonstrated that STEAP1 expression levels might influence the response of PCa cells to chemotherapeutics drugs, indicating that the use of paclitaxel, docetaxel, or cabazitaxel may lead to harmful effects in PCa cells with decreased expression of STEAP1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAntineoplastic AgentsMaleHumansDocetaxelPaclitaxelProstateCell Line, TumorTaxoidsAntigens, NeoplasmOxidoreductasesBridged-Ring Compounds

Stichwörter der Autor:innen

STEAP1cabazitaxeldocetaxelpaclitaxelprostate cancer

Substanzen

DocetaxelPaclitaxelTaxoidsAntineoplastic AgentsAntigens, NeoplasmOxidoreductasescabazitaxeltaxaneBridged-Ring CompoundsSTEAP1 protein, human

Autor:innen und Institutionen

  • CICS-UBI-Health Sciences Research Center, Universidade da Beira Interior, 6201-506 Covilhã, Portugal.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal.
  • Laboratório de Fármaco-Toxicologia-UBIMedical, Universidade da Beira Interior, 6201-284 Covilhã, Portugal.
  • C4-UBI-Cloud Computing Competence Center, Universidade da Beira Interior, 6200-501 Covilhã, Portugal.

ORCID-Profile: Sandra M Rocha, Luís A Passarinha, Sílvia Socorro, Cláudio J Maia

Förderung

  • Fundação para a Ciência e Tecnologia
  • CICS-UBI projects
  • National funds
  • FEDER funds
  • European Regional Development Fund
  • Applied Molecular Biosciences Unit UCIBIO
  • Associate Laboratory Institute for Health and Bioeconomy—i4HB
  • PPBI-Portuguese Platform of BioImaging

Zitieren

APA

Rocha, S. M., Nascimento, D., Coelho, R. S., Cardoso, A. M., Passarinha, L. A., Socorro, S., & Maia, C. J. (2023). STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076643

Vancouver

Rocha SM, Nascimento D, Coelho RS, Cardoso AM, Passarinha LA, Socorro S, et al. STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076643

BibTeX
@article{Rocha2023,
  author = {Rocha, Sandra M and Nascimento, Daniel and Coelho, Rafaella S and Cardoso, Ana Margarida and Passarinha, Luís A and Socorro, Sílvia and Maia, Cláudio J},
  title = {STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076643}
}
Kostenlos starten →